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PET-CT
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The aim was to assess the performance of prostate 3T MRI for pelvic lymph node (LN) staging in 
prostate cancer (PCa), in comparison to 68Gallium-prostate specific membrane antigen PET-CT (68Ga-
PSMA PET-CT) as reference standard for LN detection. 130 patients with PCa underwent non-contrast-
enhanced multiparametric prostate 3T MRI and 68Ga-PSMA-PET-CT within 180 days at our institution. 
Overall, 187 LN metastases (n = 43 patients) detected by 68Ga-psMA-pet-Ct were characterized 
by calculating maximum standardized uptake value (SUVmax), area, diameter and anatomical 
location including iliac, obturator, presacral and inguinal region. MRI achieved an overall sensitivity, 
specificity, positive and negative predictive value of 81.6% (CI 71.1–88.9%), 98.6% (CI 97.6–99.2%), 
73.5% (CI 52.1–87.6%) and 99.5% (CI 98.8–99.8%), respectively. On a region-based analysis, detection 
rates differed non-significantly (ps > 0.12) in the anatomical regions. On a size-dependent analysis, 
detection of LN > 10 mm did not differ significantly (ps > 0.09) from LN ≤ 10 mm. In comparison to 
single T1 sequence evaluation, additional use of the T2 weighted sequences did not improve the overall 
performance significantly (p > 0.05). 3T prostate MRI represented an accurate tool for the detection of 
LN compared to 68Ga-PSMA-PET-CT. Especially for LN metastases smaller than 10 mm, MRI was less 
accurate compared to 68Ga-psMA-pet-Ct.
Prostate cancer (PCa) is the second leading cause of death in men and the most common tumor in men in the 
western hemisphere1. Therapeutic strategies are highly dependent on the assessment of the lymph node (LN) 
status, since it affects the therapy regimen and overall prognosis in newly diagnosed PCa2. Prior to radical pros-
tatectomy, current guidelines recommend CT or MRI for local and LN staging as well as bone scintigraphy for 
osseous metastasis for patients with intermediate to high risk of recurrence according to D’Amico’s classifica-
tion2,3. Even though choline PET is associated with certain limitations regarding the sensitivity and specificity for 
LN detection, it has been established as part of the clinical routine in certain centers4. Regarding MRI, especially 
T1 and T2 sequences are known to provide excellent anatomical information to demarcate structures and are 
commonly used for evaluation of local tumor infiltrations for instance in the seminal vesicles as well as local LN 
evaluation5–12. With the introduction of 3T scanners into the clinical setting, higher signal to noise ratios could be 
realized and a more reliable detection of LN metastases could be achieved5,13–15.
Recently, PET was put back into focus for PCa staging, when novel probes targeting cell-surface receptors of 
PCa cells were introduced16–18. The prostate membrane antigen (PSMA) is a highly expressed protein located at 
the cell surface of PCa cells and the use of 68Gallium radiolabeled PSMA inhibitor Glu-urea-Lys(Ahx)-HBED-CC 
showed promising results in detection of primary and recurrent disease19,20.
The aim of this study was to assess the performance of clinical routine prostate 3T MRI for pelvic LN staging 
in PCa, compared to 68Gallium-prostate specific membrane antigen PET-CT (68Ga-PSMA PET-CT) as reference 
standard for LN detection.
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Results
Detection of lymph node metastases in MRI. Of 130 patients, 43 patients harbored 187 LN metastases 
in 68Ga-PSMA PET-CT with a mean area, size ratio and SUVmax of 0.9 ± 1.1 cm2 (range 0.1–9.2 cm2), 0.7 ± 0.2 
(range 0.3–1.5) and 10.2 ± 11.5 (range 0.7–75.5). MRI detected 146 LN with a mean area of 1.0 ± 1.2 cm2 (range 
0.1–9.1 cm2) and a size-ratio of 0.8 ± 0.5 (range 0.3–3.5). MRI achieved an overall sensitivity, specificity, PPV 
and NPV of 81.6% (CI 71.1–88.9%) 98.6% (CI 97.6–99.2%), 73.5% (CI 52.1–87.6%) and 99.5% (CI 98.8–99.8%). 
41 false negative LN had a mean area, size ratio and SUVmax of 0.4 ± 0.3 cm2 (range 0.1–1.8 cm2), 0.7 ± 0.1 
(range 0.4–1.0) and 6.1 ± 3.8 (range 0.7–18.9) in 68Ga-PSMA-PET-CT. 1130 true negative LN were measured 
in 68Ga-PSMA-PET-CT with a mean area of 0.5 ± 0.3 cm2 (range 0.1–3.5 cm2) and a size-ratio of 0.7 ± 0.2 (range 
0.2–4.5). An overall of 35 false positive LN were detected in MRI with a mean area of 1.1 ± 0.7 cm2 (range 0.2–
3.0 cm2) and a size-ratio of 0.7 ± 0.2 (range 0.4–1.0). Characteristics for all 1317 LN in 68Ga-PSMA-PET-CT are 
presented in Table 1 and descriptive statistics of the LN found in MRI are displayed in Table 2.
We thus were interested in possible impacts, that may have altered the results. The time between the two meas-
ures PET-CT and MRI varied between 0 to 180 days but the diagnostical accuracy did not suffer significantly from 
longer time intervals between the scans (χ²(2) = 1.2, p = 0.55). The impact of patients with multiple lesions to 
diagnostic accuracy was not significant (χ²(2) = 2.1,p = 0.36) and was deducted in all results given.
Detection of lymph node metastases in MRI dependent on anatomical regions. In the analysis 
dependent on anatomical regions the sensitivities differed between 66.8% and 100% while specificities ranged 
between 97.1% and 100%. The highest detection rate was presented in the inguinal region with a 100% (CI 
0–100%) followed by the obturator right and left region with 88.8% (CI 75.0–95.5%) and 84.9% (CI 62.8–95.0%). 
Presacral LN were detected with a sensitivity was 82.0% (CI 50.0–95.4%). The lowest sensitivity was presented in 
the iliac region with 80.7% (CI 60.0–92.1%) for the left and 66.8% (CI 46.6–82.2%) for the right region. Next, we 
evaluated possible differences in MRI diagnostical accuracy in the different anatomical regions. The six regions 
had a significant additional impact on diagnostical accuracy beyond the MRI judgments (χ²(10) = 18.7, p < 0.05). 
However, the source of this impact could not be pinpointed, as all single interaction effects were non-significant 
Count
Area ± SD 
[cm2] (mean)
LAdm ± SD 
[mm] (mean)
SAdm ± SD 
[mm] (mean)
Size ratio ± SD 
[mm] (mean)
All LN 1317 0.5 ± 0.5 9.2 ± 3.8 6.2 ± 2.4 0.7 ± 0.2
Iliac left 243 0.4 ± 0.6 8.3 ± 3.7 5.4 ± 2.4 0.7 ± 0.2
Iliac right 210 0.5 ± 0.8 9.2 ± 4.4 6.0 ± 2.9 0.7 ± 0.2
Obturator left 104 0.5 ± 0.6 8.2 ± 4.3 5.8 ± 3.1 0.7 ± 0.2
Obturator right 106 0.5 ± 0.6 8.9 ± 4.9 5.9 ± 2.6 0.7 ± 0.2
Presacral 26 0.3 ± 0.4 8.1 ± 2.7 6.0 ± 2.1 0.7 ± 0.1
Inguinal 628 0.6 ± 0.4 9.9 ± 3.2 6.7 ± 2.0 0.7 ± 0.2
Table 1. Characteristics of all investigated lymph nodes in 68Gallium-Prostate specific membrane antigen 
PET-CT. This table presents the main characteristics of all lymph nodes (LN) depicted in 68Gallium-Prostate 
specific membrane antigen PET-CT including all benign and malignant LN. Count, area, long-axis diameter, 
short-axis diameter and size-ratio of the LN are presented in the columns. The size ratio is described as quotient 
of short-axis diameter divided through long-axis diameter. The rows show all LN together and fielded in the 
six defined anatomical regions iliac left and right, obturator left and right, presacral and inguinal region. Data 
are given in means and standard deviations. Abbreviations: LN = Lymph nodes, LAdm = Long-axis diameter, 
SAdm = Short-axis diameter, SD = Standard deviation.
Area ± SD [cm2] 
(mean)
LAdm ± SD [mm] 
(mean)
SAdm ± SD [mm] 
(mean)
Size-ratio ± SD 
(mean)
All LN 1.0 ± 1.2 11.4 ± 6.3 8.4 ± 4.0 0.8 ± 0.5
Iliac left 1.0 ± 1.8 11.7 ± 7.3 8.7 ± 5.2 0.7 ± 0.2
Iliac right 1.3 ± 1.3 14.2 ± 6.3 9.8 ± 4.4 0.7 ± 0.2
Obturator left 1.0 ± 1.1 10.3 ± 6.6 8.3 ± 4.4 1.0 ± 0.7
Obturator right 0.8 ± 1.0 11.1 ± 5.5 7.7 ± 2.6 0.9 ± 0.6
Presacral 0.5 ± 0.4 8.6 ± 3.0 6.7 ± 2.6 0.8 ± 0.2
Inguinal 1.0 ± 1.2 12.5 ± 7.1 8.5 ± 4.8 0.7 ± 0.2
Table 2. Characteristics of all PET-positive lymph nodes depicted in MRI using T1 combined with T2 and 
DWI-sequences. This table presents the main characteristics of all malignant lymph nodes (LN) depicted 
in 68Gallium-Prostate specific membrane antigen PET-CT and MRI. Area, long-axis diameter, short-axis 
diameter and size ratio of the LN are presented in the columns. The size ratio is described as quotient of 
short-axis diameter divided through long-axis diameter. The rows show all LN together and fielded in the six 
defined anatomical regions iliac left and right, obturator left and right, presacral and inguinal region. Data 
are given in means and standard deviations. Abbreviations: LN = Lymph nodes, LAdm = Long-axis diameter, 
SAdm = Short-axis diameter, SD = Standard deviation.
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in logistic regression (ps > 0.12). Differences in the diagnostical accuracy were calculated relative to the iliac left 
region, which was arbitrary and was non-significant as can be seen at the overlapping CI of the sensitivities and 
specificities throughout the regions. Please refer to Table 3 for further details.
Assessment of histopathological data compared to MRI sensitivity. To assess a possible impact of 
histopathologic data to the readings, an interaction test was performed in this study. The diagnostical accuracy 
of MRI was significantly influenced by the results of the biopsy (χ²(1) = 4.8, p < 0.05). Sensitivity increases with 
greater Gleason scores from biopsy, i.e., p = 0.21 for a Gleason score of 6 and p = 0.97 for a score of 10. Gleason 
scores at the time of biopsy ranged from 6 to 10 with a mean of 7.8. Due to missing final Gleason scores after 
prostatectomy in most patients, no reliable statements could be made apart from biopsy.
Impact of the additional T2 and DWI sequences in lymph node staging. Since LN detection in MRI 
is commonly related to T1 sequence evaluation, we assessed the performance of T1 plus T2 and DWI compared to 
single T1 sequence evaluation. 130 LN were detected in the single T1 evaluation presenting an overall sensitivity, 
specificity, PPV and NPV of 71.8% (CI 58.2–82.3%), 99.0% (CI 98.3–99.5%), 72.2% (CI 47.9–88.0%) and 99.5% 
(CI 98.5–99.8%). Like T1 + T2, single T1 sequence evaluation displayed substantial diagnostical accuracy. Mean 
area was 1.0 ± 1.2 cm2 (range 0.1–9.1 cm2) and a mean size ratio of 0.8 ± 0.2 (range 0.3–1.) in MRI. False negative 
LN had a mean area, size ratio and SUVmax of 0.5 ± 0.3 cm2 (range 0.1–1.8 cm2), 0.7 ± 0.2 (range 0.3–1.5) and 
6.4 ± 4.0 (range 0.7–18.9) in 68Ga-PSMA-PET-CT. False positive LN had a mean area of 1.2 ± 0.7 cm2 (range 
0.3–3.0 cm2) and a size ratio of 0.7 ± 0.2 (range 0.4–1.0) in MRI. The sensitivities in single T1 sequence evaluation 
differed between 65.0% and 100% while specificities ranged between 97.7% and 100%. The highest detection 
rate was presented in the inguinal region with a 100% (CI 0–100%) followed by the presacral region with 82.3% 
(48.8–95.8%). LN in the obturator left region were detected with a sensitivity of 75.9% (CI 50.0–91.0%) followed 
by iliac left with 73.1% (CI 48.9–88.5%) and the obturator right region with 67.5% (CI 47.2–83.0%). The lowest 
sensitivity was seen in the iliac right region with 65.0% (CI 43.2–81.9%). Although the sensitivity from T1 alone 
was lower than combined with T2 + DWI, this difference was not significant, as can be seen from the overlapping 
CIs between single T1 versus T1 combined with T2 and DWI sequence evaluation. Please refer to Table 4 and 
Fig. 1 for all details.
Discussion
This study demonstrated that high resolution 3 T prostate MRI represents an accurate tool for the detec-
tion of LN metastases. Especially for LN metastases smaller than 10 mm, MRI was less accurate compared to 
68Ga-PSMA-PET-CT. In the region-based analysis, the performance of MRI was not significantly (p > 0.05) differ-
ent throughout the anatomical regions. The highest detection rate for MRI was achieved for the inguinal, obtura-
tor and presacral region, while the lowest sensitivities were achieved in the iliac regions. This may be owed to the 
challenging anatomical conditions and flow artifacts resulting from these vessels. Detection rates were higher in 
areas where LN can be better delineated from surrounding structures. Figures 2 and 3 present examples of direct 
and challenging detection of LN in PET-CT and MRI.
In comparison to single T1 sequence evaluation, T1 combined with T2 and DWI sequence evaluation showed 
no statistically significant (p > 0.05) higher overall sensitivity and in the region-based analysis, underlining the 
relevance of sole T1 sequence evaluation. An example of additional T2 sequence evaluation is presented in Fig. 4.
On a size-based analysis, LN ≤ 10 mm in the iliac, obturator and presacral region were frequently missed, 
whereas LN ≤ 10 mm were detected more reliable in all anatomical regions but no statistically significant 
(p > 0.05) lower detection rate was seen for LN ≤ 10 mm compared to LN > 10 mm. Similar non-significant 
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Table 3. Overall and region-based detection rate using combined T1 + T2 + DWI sequence MRI evaluation. 
This table summarizes the region-based analysis of the lymph node metastases in MRI using T1 combined with 
T2 and DWI sequence evaluation. The columns present number, sensitivities, specificities, positive and negative 
predictive value including 95% confidence interval. The rows are fielded in the six defined anatomical regions 
iliac left and right, obturator left and right, presacral and inguinal region. Abbreviations: LN = Lymph nodes, 
PPV = positive predictive value, NPV = Negative predictive value, CI = 95% Confidence interval.
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(p > 0.05) effects were found for single T1 sequence evaluation showing no significant additional impact of T2 
evaluation based on LN size. For additional details please refer to the supplementary dataset.
68Ga-PSMA-HBEDD-CC is an inhibitor of the glutamate carboxypeptidase II, labelled with 68Gallium21. PSMA 
is a cell-surface transmembrane protein found in the prostate, brain, lacrimal and salivary glands, tumor neo-
vasculature, tubules of the kidney and intestine22. It is a 110 kDa highly glycolysated peptidase and belongs to a 
family of zinc-dependent exopeptidases with glutamate carboxypeptidase activity22,23. It is highly active in pros-
tatic intraepithelial neoplasia and metastatic PCa22. As of today, only few numbers of studies assessed the perfor-
mance of 68Ga-PSMA PET-CT for LN staging in PCa patients and the diagnostic accuracy was tested regularly 
against histopathology as standard reference. Recently, Hamed et al. presented a prospective study with 106 out 
of 165 patients presenting with local recurrence and extraprostatic metastases, in which sensitivity, specificity 
and accuracy of 68Ga-PSMA was 99.0%, 100% and 98.8%, respectively, compared to histopathology24. In 2016, a 
study was published by Herlemann et al. on 34 patients undergoing a 68Ga-PSMA PET-CT prior to pelvic lymph 
node dissection (PLND) reporting an overall sensitivity, specificity, NPV and PPV of 84.0%, 82.0%, 84.0% and 
82.0%, respectively25. Subsequent studies also demonstrated favorable detection rates for 68Ga-PSMA PET-CT 
in comparison to histopathology26,27. These results underline the value of this imaging technique, while PLND is 
an invasive procedure associated with perioperative risks such as lymphedema and venous thromboembolism28. 
Another major limitation of histopathological assessment is the sampling error8. Skip metastases near the com-
mon and internal iliac vessels can be missed due to the limited exploration in the surgery8.
Histopathological evaluation of LN is mainly dependent on morphologic criteria such as enlarged diameter or 
rounded LN or an increased LN volume29. Another input is set through the extranodal extension of LN metasta-
ses which is defined as a perforation of the LN capsule resulting in an expansion into extranodal tissues30. In 1998 
Cheng et al. published a study including 269 patients, with LN metastases, presenting a significant correlation 
between nodal cancer volume and Gleason score recommending, that the diameter of the largest LN should be 
evaluated as prognostic factor of progression to distant metastasis rather than the number of LN30.In a follow-up 
Single T1 N Sensitivity + 95% CI Specificity + 95% CI PPV + 95 95% CI NPV + 95% CI

















































Table 4. Overall and region-based detection rate using single T1 sequence MRI evaluation. This table 
summarizes the region-based analysis of the lymph node metastases in MRI using single T1 sequence 
evaluation. The columns present number, sensitivities, specificities, positive and negative predictive value 
including 95% confidence interval. The rows are fielded in the six defined anatomical regions iliac left and right, 
obturator left and right, presacral and inguinal region. Abbreviations: LN = Lymph nodes, N = number of 
positive LN in MRI versus PET-CT, PPV = positive predictive value, NPV = Negative predictive value, CI = 95% 
Confidence interval.
Figure 1. Visualisation of the detection rates of lymph node metastases according to the used MRI sequences. 
This bar chart presents the accuracy of the detection for lymph node (LN) metastases in T1 combined with T2 
sequence evaluation versus single T1 sequence evaluation showing the overall sensitivities and specificities.
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study in 2000, Cheng et al. investigated the distant metastasis free and cancer-specific 5 year survival showing that 
extranodal extension was not significantly (p > 0.05) associated with distant metastasis free and cancer-specific 
5 year survival in contrast to nodal cancer volume which was significantly (p > 0.05) associated with poorer 5 
year survival31. A meta-analysis published in 2017 by Luchini et al. investigated the risk of recurrence through 
Figure 2. Example of a lymph node which is directly detectable on T1 MRI and 68Gallium-Prostate specific 
membrane antigen PET-CT. This figure shows a lymph node (LN) which is directly detectable on T1 MRI and 
68Gallium-Prostate specific membrane antigen PET-CT. This large suspect LN is located at the right external 
iliac artery. The LN is visualized in corresponding axial plane slices using CT, 68Gallium-Prostate specific 
membrane antigen PET-CT and T1 sequence MRI presented left to right. (A) Lymph node depicted in CT, (B) 
Lymph node depicted in 68Gallium-Prostate specific membrane antigen PET-CT; (C) Lymph node depicted in 
the T1 sequence of MRI.
Figure 3. Example of a lymph node which is challenging to detect on T1 MRI compared to the 68Gallium-
Prostate specific membrane antigen PET-CT. This figure presents an example of a lymph node close to the iliac 
bifurcation. The right and left external and internal iliac bifurcations are visualized in corresponding axial plane 
slices using CT, 68Gallium-Prostate specific membrane antigen PET-CT and T1 sequence MRI presented left 
to right. (A) Lymph node depicted in CT, (B) Lymph node depicted in 68Gallium-Prostate specific membrane 
antigen PET-CT; (C) Lymph node depicted in the T1 sequence of MRI.
Figure 4. Lymph node evaluation depicted in 68Gallium-Prostate specific membrane antigen PET-CT and 
multiparametric MRI. This figure shows an example of lymph node (LN) detection using multiparametric MRI. 
The lymph node is visualized in corresponding axial plane slices using 68Gallium-Prostate specific membrane 
antigen PET-CT, T1 and T2 sequences of MRI presented left to right. The additional use of the T2 weighted 
sequence improved the detection of a LN in risk to be missed. This suspect LN is located at the right external 
iliac artery and is challenging to depict in the T1 sequence. (A) Lymph node depicted in 68Gallium-Prostate 
specific membrane antigen PET-CT, (B) Lymph node depicted in the T1 sequence in MRI; (C) Lymph node 
depicted in the T2 sequence in MRI.
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extranodal extension resulting in an elevated risk for patients with extranodal extension in PLND to develop a 
biochemical recurrence or distant metastasis32.
Today, MRI of the prostate is a clinical routine and highly sensitive imaging procedure for staging of patients 
and detection of extracapsular and seminal vesicle infiltration due to its excellent anatomical resolution11,12. The 
performance for LN staging is still considered to be challenging12. A meta-analysis of Hövels et al. included 24 
studies with a mean sensitivity and specificity of 39.0% and 82.0% with ranges of sensitivities and specificities of 
6.0–83.0% and 65.0–99.0%, respectively for LN detection by MRI prior to PLND while magnetic field strength 
however remained unknown for all investigated studies5. Sensitivity, specificity, PPV and NPV of 71.4%, 94.7%, 
62.5% and 96.4%, respectively, were presented in a study by Kim et al. in 2010 for non-contrast enhanced T1 and 
T2 sequences of 1.5T MRI using surface coils for LN staging in comparison to histopathology6. In 2017, Gupta et al. 
reported sensitivity, specificity, PPV and NPV of 25.9%, 98.6%, 70.0% and 91.4%, respectively for LN detection 
using non contrast enhanced 1.5T MRI9.
Since area, LAdm, SAdm and size ratio are major signs for malignancy in MRI, high resolution 3T MRI 
showed an improved detection rate of small LN ≤ 10 mm in our study. Interestingly, a generally lower threshold 
for malignancy (LAdm of <10 mm) presented a better performance in comparison to histopathology than a 
higher threshold in a previous study, which is comparable to our findings5. In 2016, Barchetti et al. compared 
the performance of 1.5T MRI with non-contrast enhanced T1 plus T2 sequences in comparison to 18F-Choline 
PET-CT exams in 152 patients with biochemical recurrence reporting a sensitivity, specificity, PPV and NPV of 
98.0%, 99.0%, 97.0% and 98.0%, respectively10. This good performance of 1.5T MRI has to be seen in the context 
of the chosen reference standard. Tulsyan et al. examined the usefulness of 68Ga-PSMA PET-CT in 36 patients 
with a biopsy proven PCa with a minimum Gleason score of 8 and PSA blood levels >20 ng/ml for LN staging in 
comparison to non-contrast enhanced 1.5T MRI11. 29 out of 36 patients presented LN in 68Ga-PSMA PET-CT in 
contrast to 20 MRI positive patients, which resulted in a concordance of 72% between both modalities without 
sensitivities or specificities given in the manuscript11.
Regarding the use of 3T MRI, Zattoni et al. published a study on recurrent PCa after failure of primary radia-
tion therapy using histopathology as reference standard for LN detection by contrast enhanced 3T MRI applying 
an endorectal coil. They reported a sensitivity and specificity of 60.0% and 85.7%, respectively, for an unknown 
number of LN15. A further study from Zhang et al. compared contrast enhanced multiparametric MRI at 3T and 
68Ga-PSMA PET-CT against histopathology for a cohort of 42 patients prior undergoing radical prostatectomy 
with PLND and found to be equal regarding the diagnostic accuracy14. A total of 51 LN out of 621 resected LN 
were defined malignant in histopathology and sensitivities, specificities, PPV and NPV of 96.1%, 99.5%, 94.2% 
and 99.7% for MRI and 96.1%, 99.7%, 96.1% and 99.7% for 68Ga-PSMA PET-CT were reported14. In our study 
68Ga-PSMA-PET-CT was set as reference standard with an overall sensitivity, specificity, PPV and NPV of 81.6%, 
98.6%, 73.5% and 99.5% for MRI.
In contrast to our study, Zhang et al. did not present LN detection rates according to anatomical regions while 
showing a higher overall detection rates with comparable results in the size-based analysis compared to our study. 
This may be due to the rather small cohort of 42 patients and the elevated mean PSA blood level with 52.3 ng/ml 
in Zhang et al. compared to 15.8 ng/ml in our study. Furthermore, the delay between PET-CT, MRI and surgery 
remained unknown. Moreover, the used malignancy criteria for MRI in Zhang et al. were SAdm > 10 mm, a 
rounded LN with a SAdm > 8 mm, increased contrast enhancement or a diffusion restriction in DWI and ADC 
map14. Our study chose a stricter malignancy criteria with a LAdm excess of 10 mm or a rounded LN defined 
through the quotient of SAdm divided through LAdm was present. In contrast to Zhang et al., the investigated 
MRI sequences in this study did not include the examination of DCE sequences and no use of contrast agent in 
our study, since gadolinium is associated with certain risks including nephrogenic systemic fibrosis especially in 
patients with chronic kidney disease33.
In summary, higher PSA blood levels may indicate more advanced tumor stages, the unknown delay of the 
procedures, the additional use of DCE sequences and contrast agent may have resulted in the slightly higher 
detection rates in Zhang et al. compared to our study. The comparable results of our study underline the validity 
of 68Ga-PSMA-PET-CT as reference standard compared to histopathology.
Limitations are the retrospective character of this study and the relatively small number of patients involved. 
No histopathological confirmation of the metastases seen in 68Ga-PSMA PET-CT was performed. A delay of up 
to 180 days between both imaging techniques might have influenced the size of the LN, but because PCa is a slow 
growing cancer entity, this time delay was considered of minor relevance. The performance of MRI detection 
was shortened through challenging localization near big vessels, and therefore interobserver variability cannot 
be excluded. Pitfalls of physiological tracer uptake were limited through parallel evaluation in CT. Size variations 
or necrosis of LN may have biased the examination as well. Given that size is a determining factor of malig-
nancy in MRI, the size-based analysis could be biased leading to better sensitivities for LN > 10 mm compared 
to LN ≤ 10 mm. To limit this effect, the examination was done by two experienced readers and a size ratio was 
included to detect small but malignant LN based on a previous study in T1 sequences29.
In conclusion, high resolution 3T prostate MRI represents an accurate tool for the detection of LN metas-
tases. The detection rates of MRI were lower for metastases in complex anatomical regions, compared to 
68Ga-PSMA PET-CT. Especially for LN metastases smaller than 10 mm, MRI was less accurate compared to 
68Ga-PSMA-PET-CT. The authors suggest that 68Ga-PSMA-PET-CT should be used for primary lymph node 
staging and for patients with biochemical recurrence.
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Methods
study population. The institutional ethics review board of the Department of Radiology at the Charité 
Universitätsmedizin Berlin, Germany approved this retrospective study and it was performed in accordance to 
current guidelines. The local database was screened for patients, who received a 68Ga-PSMA PET-CT and a 3 Tesla 
prostate MRI within 180 days. 1170 patients received a 68Ga-PSMA PET-CT between October 2013 and May 
2018. No MRI or external MRI was available in the local database in 855 cases. 185 cases exceeded the maximum 
time interval of 180 days. The remaining cohort consisted of 130 patients. All Patients had histological proven 
prostate cancer with mean age of 72.1 ± 7.5 years (range 51–89 years) and received a 68Ga-PSMA PET-CT and a 
3T MRI within 72.7 ± 48.4 days (range 0–180 days). The mean delay between diagnosis and the first examined 
scan (PET-CT or MRI) in this study was 1.7 ± 3.4 years (range 0–17 years) with a median of 0 years. When multi-
ple studies were present, the scans with the shortest delay were used in this investigation. All other examinations 
were not used as part of the reading. Patients in this study did not receive any surgery, radiotherapy, change in 
the regime of chemotherapy or change of hormonal treatment within the delay between both modalities. There 
was no artificial delay of treatment in the patients investigated in this study. Prostate specific antigen (PSA) blood 
levels were 15.8 ± 23.6 ng/ml (range 0.2–196 ng/ml) collected within 26.5 ± 43.0 days (range 0–193 days) to the 
68Ga-PSMA PET-CT and a median core needle biopsy Gleason score of 8 (range 6–10) was reported. Patients 
characteristics are presented in Table 5.
68Ga-PSMA PET-CT and 3T MRI acquisition protocols. A standard 68Ge/68Ga generator (Eckert 
and Ziegler) was used for elution of 68Ga prior to labelling with PSMA-HBED-CC (ABX GmbH, Radeberg, 
Germany)22,23,34. After injection of 129.0 ± 26.2MBq of 68Ga-PSMA-HBED-CC, a low dose CT for attenuation 
correction (120 kVp, 30 mAs) and anatomical mapping was acquired within 89.0 ± 42.5 min immediately before 
the PET scan, using a Gemini TF 16 Astonish PET-CT scanner (Philips medical systems)35. All 130 patients 
underwent a non-contrast-enhanced prostate multiparametric MRI at our institution at 3T (Magentom Skyra, 
Siemens Healthcare, Erlangen, Germany). Standard prostate MRI acquisition protocol included high resolution 
T2 weighted high resolution turbo spin echo sequences (T2 HR TSE, 25 slices, thickness 3 mm, gap 3 mm, TR 
4040 ms, TE 116 ms, resolution: 0.47 × 0.47 mm), including DWI sequences (DWI, 25 slices, thickness 3 mm, gap 
3 mm, TR 4800 ms, TE 58 ms, resolution 1.4 × 1.4 mm and b-factors 0/160/1200 s/mm2) with generation of an 
ADC map from b 0, b 160 and b 1200 images of the DWI. Native T1 high resolution isotropic volume sequences 
(T1 TSC, 49 slices thickness 5 mm, gap 6 mm, TE 11 ms, TR 800 ms, resolution 0.63 × 0.63 mm). No endorectal 
coils were used throughout all exams.
Image analysis. Visage 7.1 (Visage Imaging) was used as the standard software package. Low dose whole 
body CT sequences and 68Ga-PSMA PET sequences were automatically fused for the evaluation process. Since the 
acquisition of a MRI of the pelvis is limited to a localized area while 68Ga-PSMA PET-CT covered the whole body, 
the aortic bifurcation was set as the upper border for positive LN in 68Ga-PSMA PET-CT. Consensus reading was 
performed by two readers. All images were analysed independently in a blinded and random order.
Assessment of lymph node metastasis in MRI. For LN examination in 3T MRI data sets, T1 TSE, T2 
TSE and DWI sequences were used. T1 sequences were used in the first step, followed by high resolution T2 TSE 
and DWI to assess their additional value. The diameter of suspicious LN were measured in axial planes through 
manual delineation of a ROI, resulting in size, long-axis diameter (LAdm) and short axis diameter (SAdm). SAdm 
was defined as the rectangular line of the LAdm. A LN was defined as positive in MRI when the SAdm divided 
through LAdm exceeded the size ratio of 0.8 or if the LAdm was ≥10 mm, based on a previous study on LN 
detection in T1 sequences29. Signal intensity was no criteria for definition of a LN as metastatic. The size ratio is 
reported throughout the manuscript. All LN were characterized in six levels according to the adjacent anatomical 
structures dividing them into presacral, inguinal LN and alongside the large arterial vessels. LN alongside the 
mean SD median range
Age (years) 72.1 7.5 73 51–89
Days 68GA-PSMA-PET to MRI 72.7 48.4 63 0–180
Days PSA to 68GA-PSMA-PET 26.5 43 0 0–193
PSA (ng/ml) 15.8 23.6 9.7 0.2–196
T-Stage 2.5 0.7 2.5 1–4
Prostate volume (ml) 68.8 36.0 68 10–188
Gleason score biopsy 7, 9 1.0 8 6–10
Gleason score after surgery 7.7 0.9 7 7–9
Table 5. Basic characteristics of study collective. The basic characteristics of the prostate cancer patients who 
received a 68Gallium-Prostate specific membrane antigen (68Ga-PSMA) PET-CT and a multiparametric MRI 
within 180 days investigated in this study are presented in this table. This included the age of the patients, the 
delay between both imaging modalities, the prostate specific antigen blood level, the delay towards the 68Ga-
PSMA PET-CT, prostate volumes, the Gleason scores from biopsy and after surgery and the tumor stages. 
Data are given in means, standard deviations, medians and ranges. Abbreviations: PSMA = Prostate specific 
membrane antigen, PET = Positron emission tomography, MRI = Magnetic resonance imaging, PSA = Prostate 
specific antigen blood level.
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common and external iliac arteries were characterized as the iliac right and iliac left region as superordinate levels 
and LN near the internal iliac and obturator artery were characterized as obturator right and obturator left region. 
Please refer to Fig. 5 for visualization of the defined regions.
Measurement of lymph node metastasis in 68Ga-psMA pet-Ct. All 68Ga-PSMA avid LN were meas-
ured in the axial plane at maximum diameter using the CT sequence for delineation of the ROI after evaluation of 
tracer uptake in 68Ga-PSMA PET overlay at isocontour of 50%. LN were defined positive, when an abnormal focal 
tracer signal with a higher signal intensity than the surrounding background was detected in 68Ga-PSMA PET 
and a LN in CT could be allocated to the signal14. LN size evaluation did not affect the definition of positivity in 
68Ga-PSMA PET-CT, which is comparable to a previously published study14. In addition, maximum standardized 
uptake values (SUVmax) were assessed. All visible LN on CT without tracer uptake were measured in LAdm and 
SAdm to be defined as true negatives. All LN depicted in PET-CT were divided into the 2 subgroups LN > 10 mm 
and LN ≤ 10 mm. MRI sensitivity was calculated for both size groups and for each anatomical region. Please refer 
to Fig. 6 for an example of a LN < 10 mm and Fig. 7 for a LN > 10 mm using PET-CT and MRI.
statistical analysis. 68Ga-PSMA PET-CT was set as reference standard in this study.
Descriptive statistics were done using MedCalc Statistical Software version 17.6 (MedCalc Software bvba; 
http://www.medcalc.org; 2017) and R software (Version 3.5.0, Vienna, Austria, https://www.R-project.org, 
+lme4-package) was used for multi-level logistic regression. We used logistic regression in order to assess the 
diagnostic quality of MRI in contrast to our gold standard. The overall fit of a logistic regression model corre-
sponds to the overall predictive accuracy and is as such related to comparable analysis techniques like ROC anal-
ysis. We utilized likelihood-ratio chi-square tests to calculate p-values within logistic regression. More specifically, 
we applied multi-level logistic regression to satisfy our hierarchical data structure (lymph nodes within patients) 
Multi-level regression adjusts for clusterings in data, i.e., for effects that some patients a conspicuous lymph 
Figure 5. Template of Lymph node stations used in the region-based analysis. This figure shows the template 
of the lymph node (LN) stations examined in this study. The iliac left and right region included all LN around 
the common iliac and external iliac artery. The obturator left and right region included all LN around the 
internal iliac artery and its branches. The presacral region defined the area anterior of the sacrum without strict 
allocation to vessels. LN of the inguinal region were defined below the inguinal bands.
Figure 6. Example of a lymph node smaller than 10 mm in 68Gallium-Prostate specific membrane antigen 
PET-CT compared to T1 MRI. This figure shows a suspicious lymph node smaller than 10 mm diameter. The 
lymph node is visualized in corresponding axial plane slices using CT, 68Gallium-Prostate specific membrane 
antigen PET-CT and T1 MRI from left to right. The suspected lymph node is located at the right common iliac 
artery and is challenging to detect in T1 MRI. The lymph node is highlighted through red arrows. (A) Lymph 
node depicted in CT, (B) Lymph node depicted in 68Gallium-Prostate specific membrane antigen PET-CT, (C) 
Lymph node depicted in the T1 sequence in MRI.
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node might be more likely to have more conspicuous lymph nodes36. Multi-level models include such effects and 
can even capture person-wise differences in diagnostic accuracy (called random slope models). In our analyses 
below, we tested for each predictive model whether such person-wise differences were statistically significant. The 
common properties of a diagnostical test (sensitivity, specificity, positive predictive value and negative predictive 
value) were calculated from logistic regression and confidence intervals (CI 95%) were given through logistic 
regression using the method proposed by Coughlin et al.37. When no confidence intervals could be calculated 
due to perfect agreement of MRI and PET-CT, it is highlighted in the tables. A p-value p < 0.05 was considered 
statistically significant.
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